<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4327">
  <stage>Registered</stage>
  <submitdate>31/01/2014</submitdate>
  <approvaldate>31/01/2014</approvaldate>
  <nctid>NCT02078609</nctid>
  <trial_identification>
    <studytitle>A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)</studytitle>
    <scientifictitle>A Phase I, Multicenter, Open-label Study of Oral LGH447 in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-003756-20</secondaryid>
    <secondaryid>CLGH447X2102</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>AML and High Risk MDS</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LGH447
Treatment: drugs - LGH447 + midostaurin

Experimental: LGH447 monotherapy arm - LGH447 monotherapy in patients with AML or MDS

Experimental: LGH447 + midostaurin combination arm - LGH447 + midostaurin in patients with AML


Treatment: drugs: LGH447
LGH447 in patients with AML or MDS

Treatment: drugs: LGH447 + midostaurin
LGH447 + midostaurin in patients with AML

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence rate of dose limiting toxicities (DLTs) of LGH447 monotherapy arm in patients with AML or MDS and of LGH447 + midostaurin in patients with AML - Frequency and characteristics of dose limiting toxicities</outcome>
      <timepoint>28 days post study treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with the type, frequency, and severity of adverse events (AEs) as a measure of safety and tolerability of the LGH447 monotherapy arm in patients with AML or MDS and of the LGH447 + midostaurin treatment arm in patients with AML - Includes changes in hematology and blood chemistry values, assessments of physical examinations, vital signs, and electrocardiograms (ECGs)</outcome>
      <timepoint>weekly to bi-weekly up to 1.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters of the LGH447 monotherapy arm in patients with AML or MDS and of the LGH447 + midostaurin treatment arm in patients with AML - LGH447 and midostaurin plasma concentrations and basic PK parameters</outcome>
      <timepoint>days 1, 2, 15, 16, 29, 30, 44, 57, and approximately monthly through Cycle 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes between pre- and post-treatment levels of pS6RP and p4EBP1 in bone marrow aspirates and p4EBP1 in peripheral blood of the LGH447 monotherapy arm in patients with AML or MDS and of the LGH447 + midostaurin treatment arm in patients with AML - Assess pharmacodynamic effects of LGH447</outcome>
      <timepoint>screening, days 1 and 29 up to 1.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-tumor activity in AML or high risk MDS associated wtih LGH447 - To assess any preliminary anti-tumor activity in AML or high risk MDS associated with LGH447</outcome>
      <timepoint>Day 29 up to 1.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-tumor activity in AML or high risk MDS associated wtih LGH447 in combination with midostaurin - To assess any preliminary anti-tumor activity in AML or high risk MDS associated with LGH447 in combination with midostaurin</outcome>
      <timepoint>Day 29 up to 1.5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

        -Male or female patients =18 years of age who present with one of the following:

        LGH447 monotherapy arm

          -  Refractory/Relapsed AML following no more than 2 prior therapies, or in previously
             untreated AML patients who are not candidates for standard therapy.

          -  High and very high risk MDS according to the revised International Prognostic Scoring
             System (rIPSS) who have failed prior therapies, such as azacitidine and decitabine

          -  Patients with rIPSS score of &gt; 4.5

        LGH447 and midostaurin combination arm

          -  Refractory/Relapsed AML following no more than 2 prior therapies, or in previously
             untreated AML patients who are not candidates for standard therapy. AML patients may
             have either FLT3 wild type or FLT3-ITD/TKD mutant disease, and FLT3 mutation status
             needs to be defined at study entry.

               -  For AML patients, peripheral blast counts &lt; 50,000 blasts/mm3

               -  For MDS patients;

          -  Platelet count &gt; 25,000/mm3

          -  Neutrophils &gt; 500/mm3

          -  Blood transfusions are allowed to maintain clinically adequate hemoglobin and
             hematocrit levels

               -  Patients with active central nervous system (CNS) disease are eligible to
                  participate and may be treated concurrently with intrathecal (or intra Ommaya)
                  chemotherapy

               -  Patients who are maintained on prophylactic antibiotics are eligible to
                  participate as long as agents comply with the list of approved concomitant
                  medications

               -  Performance status = 2

               -  Meet other lab criteria</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  Systemic antineoplastic therapy (including unconjugated therapeutic antibodies and
             toxin immunoconjugates) or any experimental therapy within 7 days or 5 half-lives,
             whichever is longer, before the first dose of LGH447 monotherapy or LGH447 in
             combination with midostaurin

          -  Radiotherapy with a wide field of radiation within 28 days or radiotherapy with a
             limited field of radiation for palliation within 7 days of the first dose of LGH447
             monotherapy or LGH447 in combination with midostaurin

          -  Patients who received CNS irradiation for meningeal leukemia, except if radiotherapy
             occurred &gt; 3 months previously

          -  Major surgery within 4 weeks before the first dose of LGH447 monotherapy or LGH447 in
             combination with midostaurin

          -  Ongoing therapy with corticosteroids greater than 10 mg of prednisone or its
             equivalent per day. Inhaled and topical steroids are permitted

          -  Patients who are currently receiving hydroxyurea to control peripheral blood leukemic
             blasts and cannot be discontinued for at least 48 hours prior to obtaining PD
             biomarkers at screening/baseline and during the study

          -  Patients who are currently receiving treatment with prohibited medication and that
             cannot be discontinued at least one week prior to the start of treatment with LGH447
             monotherapy or LGH447 in combination with midostaurin

          -  Active infection requiring systemic therapy or other severe infection, including
             pneumonia, within 2 weeks before the first dose of LGH447 monotherapy or LGH447 in
             combination with midostaurin

          -  Known human immunodeficiency virus (HIV) positive

          -  Corrected QT interval (QTc) of &gt; 450 milliseconds (ms) in males and &gt; 470 milliseconds
             (ms) in females on baseline electrocardiogram (ECG) (using corrected QT interval using
             Fridericia [QTcF] or local standards).

          -  Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias,
             congestive heart failure, angina, or myocardial infarction within the past 6 months

          -  Pregnant or nursing</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>20/03/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>86</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>3/09/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Prahran</hospital>
    <postcode>3181 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>RM</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will assess the safety and preliminary efficacy of escalating doses of LGH447
      monotherapy in AML and MDS and LGH447 in combination with midostaurin in AML.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02078609</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address />
      <phone>1-888-669-6682</phone>
      <fax />
      <email>Novartis.email@novartis.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>